Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Wondercell Closes $14 Million in Angel Funding for Immune Cell Therapies

publication date: Feb 13, 2023

Wondercel Therapeutics, a Shenzhen next-gen immune cell therapy company, raised $14 million in an angel round from Yuansheng Venture, the only investor in the funding. Wondercel is led by the former CSO and Co-Founder of Nanjing’s Legend Biotech, Xiaohu Fan. Legend made its name by developing the first CAR-T therapy in China, Carvykti, an autologous BCMA targeting CAR-T approved in China, the US and EU for multiple myeloma. Dr Fan has said the new company will develop safer and less-expensive immune cell therapies for oncology, organ transplantation and autoimmune diseases. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital